Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prime Medicine (PRME) Receivables (2024 - 2025)

Prime Medicine filings provide 2 years of Receivables readings, the most recent being $4.6 million for Q4 2025.

  • On a quarterly basis, Receivables rose 185.02% to $4.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $4.6 million, a 185.02% increase, with the full-year FY2025 number at $4.6 million, up 185.02% from a year prior.
  • Receivables hit $4.6 million in Q4 2025 for Prime Medicine, up from $120000.0 in the prior quarter.
  • In the past five years, Receivables ranged from a high of $55.0 million in Q3 2024 to a low of $17000.0 in Q1 2025.